SCHEMBL3149360

SCHEMBL3149360

O=C(NCCN1CCCCC1)c1ccc(S(=O)(=O)N(Oc2ccccc2)c2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.59
CA9 Q16790 2/20 0.59
POLB P06746 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
GLA P06280 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 3/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CA1 P00915 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MCHR1 Q99705 1/20 0.45
HPGD P15428 2/20 0.45
CD274 Q9NZQ7 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3050759 0.89 CA12 (0.47) CA12CA9POLBALDH1A1NPC1
SCHEMBL3148954 0.86 PSEN1 (0.47) CA12CA9ALDH1A1SMN1; SMN2HRH3
SCHEMBL3139317 0.86 CA1 (0.49) CA12CA9CA1NPC1RAB9A
SCHEMBL3274986 0.86 NPC1 (0.46) CA12CA9L3MBTL1ALDH1A1NPC1
SCHEMBL3149086 0.84 CA12 (0.49) CA12CA9ALDH1A1NPC1RAB9A
SCHEMBL3278529 0.84 NPC1 (0.44) CA12CA9L3MBTL1ALDH1A1NPC1
SCHEMBL15103782 0.84 NPC1 (0.52) L3MBTL1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL15103797 0.84 NPC1 (0.52) L3MBTL1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL15103734 0.84 NPC1 (0.52) L3MBTL1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3149836 0.84 CCR2 (0.50) CA12CA9ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 CA12 2341/4885CA9 1719/4885POLB 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.